Skip to main content
Top
Published in: European Radiology 9/2014

01-09-2014 | Cardiac

Comparison of acquisition time and dose for late gadolinium enhancement imaging at 3.0 T in patients with chronic myocardial infarction using Gd-BOPTA

Authors: A. Doltra, A. Skorin, A. Hamdan, B. Schnackenburg, R. Gebker, C. Klein, E. Nagel, E. Fleck, S. Kelle

Published in: European Radiology | Issue 9/2014

Login to get access

Abstract

Objectives

To compare contrast doses and acquisition times for late gadolinium enhancement (LGE) imaging at 3.0 T using gadobenate dimeglumine (Gd-BOPTA) in patients with chronic myocardial infarction.

Methods

Thirty-four patients with chronic myocardial infarction were randomised to 0.10, 0.15 and 0.20 mmol/kg of Gd-BOPTA. T1-weighted inversion recovery gradient echo sequences were performed at 5, 10, 15 and 20 min post-administration of contrast in a 3.0-T scanner. Scar-to-myocardium contrast-to-noise ratio (CNR), scar-to-blood CNR, scar size and image quality were assessed.

Results

Imaging at 5 min was associated with a lower scar-to-blood CNR in comparison to 10, 15 and 20 min at 0.10 mmol/kg, and in comparison to 15 and 20 min at 0.20 mmol/kg. At 0.10-mmol/kg, imaging at 5 min yielded smaller infarct sizes in comparison to 15 and 20 min. Finally, at 0.20-mmol/kg, imaging at 5 min was associated with poorer image quality in comparison to later times.

Conclusions

In LGE imaging at 3.0 T, low doses of Gd-BOPTA perform equally well as higher doses. Early acquisition (5 min) is associated with lower infarct sizes and image quality. Studies with sufficient diagnostic quality can be obtained after 10 min using 0.10 mmol/kg Gd-BOPTA.

Key points

Good performance of low Gd-BOPTA doses for LGE imaging at 3.0 T.
Imaging at 5 min yields lower contrast, infarct sizes and image quality.
Diagnostic quality can be obtained after 10 min using 0.10-mmol/kg Gd-BOPTA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hundley WG, Bluemke DA, Finn JP et al (2010) ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 55:2614–2662PubMedCrossRef Hundley WG, Bluemke DA, Finn JP et al (2010) ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 55:2614–2662PubMedCrossRef
2.
go back to reference Bruder O, Wagner A, Lombardi M et al (2013) European Cardiovascular Magnetic Resonance (EuroCMR) registry—multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson 15:9PubMedCentralPubMedCrossRef Bruder O, Wagner A, Lombardi M et al (2013) European Cardiovascular Magnetic Resonance (EuroCMR) registry—multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson 15:9PubMedCentralPubMedCrossRef
3.
go back to reference Klumpp B, Fenchel M, Hoevelborn T et al (2006) Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla. Invest Radiol 41:661–667PubMedCrossRef Klumpp B, Fenchel M, Hoevelborn T et al (2006) Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla. Invest Radiol 41:661–667PubMedCrossRef
4.
go back to reference Klumpp BD, Sandstede J, Lodemann KP et al (2009) Intraindividual comparison of myocardial delayed enhancement MR imaging using gadobenate dimeglumine at 1.5 T and 3 T. Eur Radiol 19:1124–1131PubMedCrossRef Klumpp BD, Sandstede J, Lodemann KP et al (2009) Intraindividual comparison of myocardial delayed enhancement MR imaging using gadobenate dimeglumine at 1.5 T and 3 T. Eur Radiol 19:1124–1131PubMedCrossRef
5.
go back to reference Kim RJ, Albert TS, Wible JH et al (2008) Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 117:629–637PubMedCrossRef Kim RJ, Albert TS, Wible JH et al (2008) Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 117:629–637PubMedCrossRef
6.
go back to reference Wagner A, Mahrholdt H, Thomson L et al (2006) Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47:2027–2033PubMedCrossRef Wagner A, Mahrholdt H, Thomson L et al (2006) Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47:2027–2033PubMedCrossRef
7.
go back to reference Pedersen M (2007) Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 25:881–883PubMed Pedersen M (2007) Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 25:881–883PubMed
8.
go back to reference Penfield JG, Reilly RF Jr (2007) What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 3:654–668PubMedCrossRef Penfield JG, Reilly RF Jr (2007) What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 3:654–668PubMedCrossRef
9.
go back to reference Look DC, Locker DL (1970) Time saving measurement of NMR and EPR relaxation times. Rev Sci Instrum 41:250–251CrossRef Look DC, Locker DL (1970) Time saving measurement of NMR and EPR relaxation times. Rev Sci Instrum 41:250–251CrossRef
10.
go back to reference Flett AS, Hasleton J, Cook C et al (2011) Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 4:150–156PubMedCrossRef Flett AS, Hasleton J, Cook C et al (2011) Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 4:150–156PubMedCrossRef
11.
go back to reference Klinke V, Muzzarelli S, Lauriers N et al (2013) Quality assessment of cardiovascular magnetic resonance in the setting of the European CMR registry: description and validation of standardized criteria. J Cardiovasc Magn Reson 15:55PubMedCentralPubMedCrossRef Klinke V, Muzzarelli S, Lauriers N et al (2013) Quality assessment of cardiovascular magnetic resonance in the setting of the European CMR registry: description and validation of standardized criteria. J Cardiovasc Magn Reson 15:55PubMedCentralPubMedCrossRef
12.
go back to reference Oppo K, Leen E, Angerson WJ, Cooke TG, McArdle CS (1998) Doppler perfusion index: an interobserver and intraobserver reproducibility study. Radiology 208:453–457PubMedCrossRef Oppo K, Leen E, Angerson WJ, Cooke TG, McArdle CS (1998) Doppler perfusion index: an interobserver and intraobserver reproducibility study. Radiology 208:453–457PubMedCrossRef
13.
go back to reference Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ (2005) Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26:1461–1474PubMedCrossRef Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ (2005) Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26:1461–1474PubMedCrossRef
14.
go back to reference Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM (2001) Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 104:1101–1107PubMedCrossRef Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM (2001) Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 104:1101–1107PubMedCrossRef
15.
go back to reference Kim RJ, Wu E, Rafael A et al (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:1445–1453PubMedCrossRef Kim RJ, Wu E, Rafael A et al (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:1445–1453PubMedCrossRef
16.
go back to reference Roes SD, Kelle S, Kaandorp TA et al (2007) Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol 100:930–936PubMedCrossRef Roes SD, Kelle S, Kaandorp TA et al (2007) Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol 100:930–936PubMedCrossRef
17.
go back to reference Kwong RY, Sattar H, Wu H et al (2008) Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 118:1011–1020PubMedCentralPubMedCrossRef Kwong RY, Sattar H, Wu H et al (2008) Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 118:1011–1020PubMedCentralPubMedCrossRef
18.
go back to reference Kelle S, Roes SD, Klein C et al (2009) Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 54:1770–1777PubMedCrossRef Kelle S, Roes SD, Klein C et al (2009) Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 54:1770–1777PubMedCrossRef
19.
go back to reference Kelle S, Nagel E, Voss A et al (2013) A bi-center cardiovascular magnetic resonance prognosis study focusing on dobutamine wall motion and late gadolinium enhancement in 3,138 consecutive patients. J Am Coll Cardiol 61:2310–2312PubMedCrossRef Kelle S, Nagel E, Voss A et al (2013) A bi-center cardiovascular magnetic resonance prognosis study focusing on dobutamine wall motion and late gadolinium enhancement in 3,138 consecutive patients. J Am Coll Cardiol 61:2310–2312PubMedCrossRef
20.
go back to reference Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E (2008) Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 10:35PubMedCentralPubMedCrossRef Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E (2008) Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 10:35PubMedCentralPubMedCrossRef
21.
go back to reference Li Y, Li X, Li D et al (2013) Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study). AJNR Am J Neuroradiol 34:847–854PubMedCrossRef Li Y, Li X, Li D et al (2013) Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study). AJNR Am J Neuroradiol 34:847–854PubMedCrossRef
22.
go back to reference Wang J, Yan F, Liu J et al (2013) Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study). J Magn Reson Imaging 38:926–937PubMed Wang J, Yan F, Liu J et al (2013) Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study). J Magn Reson Imaging 38:926–937PubMed
23.
go back to reference Gerretsen SC, le Maire TF, Miller S et al (2010) Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 255:988–1000PubMedCrossRef Gerretsen SC, le Maire TF, Miller S et al (2010) Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 255:988–1000PubMedCrossRef
24.
go back to reference Bueltmann E, Erb G, Kirchin MA, Klose U, Naegele T (2008) Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla. Invest Radiol 43:695–702PubMedCrossRef Bueltmann E, Erb G, Kirchin MA, Klose U, Naegele T (2008) Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla. Invest Radiol 43:695–702PubMedCrossRef
25.
go back to reference Klein C, Nekolla SG, Balbach T et al (2004) The influence of myocardial blood flow and volume of distribution on late Gd-DTPA kinetics in ischemic heart failure. J Magn Reson Imaging 20:588–593PubMed Klein C, Nekolla SG, Balbach T et al (2004) The influence of myocardial blood flow and volume of distribution on late Gd-DTPA kinetics in ischemic heart failure. J Magn Reson Imaging 20:588–593PubMed
26.
go back to reference Pintaske J, Martirosian P, Graf H et al (2006) Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 41:213–221PubMedCrossRef Pintaske J, Martirosian P, Graf H et al (2006) Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 41:213–221PubMedCrossRef
Metadata
Title
Comparison of acquisition time and dose for late gadolinium enhancement imaging at 3.0 T in patients with chronic myocardial infarction using Gd-BOPTA
Authors
A. Doltra
A. Skorin
A. Hamdan
B. Schnackenburg
R. Gebker
C. Klein
E. Nagel
E. Fleck
S. Kelle
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 9/2014
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-014-3213-y

Other articles of this Issue 9/2014

European Radiology 9/2014 Go to the issue